Subunits of BK channels promote breast cancer development and modulate responses to endocrine treatment in preclinical models. (27th August 2020)

• Record Type: Journal Article
• Authors: Mohr, Corinna J.; Schroth, Werner; Mürdter, Thomas E.; Gross, Dominic; Maier, Selina; Stegen, Benjamin; Dragoi, Alice; Steudel, Friederike A.; Stehling, Severine; Hoppe, Reiner; Madden, Stephen; Ruth, Peter; Huber, Stephan M.; Brauch, Hiltrud; Lukowski, Robert
• Other Names: Stefanska Barbara guestEditor.; Tucker Steven guestEditor.; MacEwan David guestEditor.
• Is Part Of: British journal of pharmacology. Volume 179:Number 12(2022)
• Page Start: 2906
• Page End: 2924
• Publication Date: 2020-08-27
• Subjects: breast cancer -- estrogen receptor -- leucine‐rich repeat 49 containing 26 -- mouse mammary tumour virus polyoma middle T antigen -- selective Estrogen Receptor Modulator 51 -- tamoxifen -- Voltage‐ and Ca2+‐activated K+ channels of big conductance; Pharmacology -- Periodicals; Chemotherapy -- Periodicals; Drug Therapy -- Periodicals; Pharmacology -- Periodicals; 615.1
• DOI: 10.1111/bph.15147
• Languages: English
• ISSNs: 0007-1188

Abstract

Abstract : Background and Purpose: Pore‐forming α subunits of the voltage‐ and Ca 2+ ‐activated K + channel with large conductance (BKα) promote malignant phenotypes of breast tumour cells. Auxiliary subunits such as the leucine‐rich repeat containing 26 (LRRC26) protein, also termed BKγ1, may be required to permit activation of BK currents at a depolarized resting membrane potential that frequently occur in non‐excitable tumour cells. Experimental Approach: Anti‐tumour effects of BKα loss were investigated in breast tumour‐bearing MMTV‐PyMT transgenic BKα knockout (KO) mice, primary MMTV‐PyMT cell cultures, and in a syngeneic transplantation model of breast cancer derived from these cells. The therapeutic relevance of BK channels in the context of endocrine treatment was assessed in human breast cancer cell lines expressing either low (MCF‐7) or high (MDA‐MB‐453) levels of BKα and BKγ1, as well as in BKα‐negative MDA‐MB‐157. Key Results: BKα promoted breast cancer onset and overall survival in preclinical models. Conversely, lack of BKα and/or knockdown of BKγ1 attenuated proliferation of murine and human breast cancer cells in vitro. At low concentrations, tamoxifen and its major active metabolites stimulated proliferation of BKα/γ1‐positive breast cancer cells, independent of the genomic signalling controlled by the oestrogen receptor. Finally, tamoxifen increased the relative survival time of BKα KO but not of wild‐type tumour cell recipient mice. Conclusion and Implications: Breast cancer initiation, progression, and tamoxifen sensitivity depend on functional BK channels thereby providing a rationale for the future exploration of the oncogenic actions of BK channels in clinical outcomes with anti‐oestrogen therapy. LINKED ARTICLES: This article is part of a themed issue on New avenues in cancer prevention and treatment (BJP 75th Anniversary). To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.12/issuetoc